CVS·CVS Health Corporation
CVS|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $1.64 | - | - |
| Q2'26 | $1.87 | $2.58 | +38.0% |
| Q1'26 | $2.21 | $2.57 | +16.5% |
| Q4'25 | $1.00 | $1.09 | +8.8% |
| Q3'25 | $1.36 | $1.60 | +17.9% |
| Q2'25 | $1.46 | $1.81 | +23.9% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q3'26 | $105.2B | - | - |
| Q2'26 | $101.1B | $106.1B | +4.9% |
| Q1'26 | $95.0B | $100.4B | +5.7% |
| Q4'25 | $104.6B | $105.7B | +1.0% |
| Q3'25 | - | $102.9B | - |
| Q2'25 | - | $98.9B | - |
Market Data
CVS Stock Snapshot
CVS is currently trading at $93.02, giving CVS Health Corporation a market cap of 122.46B and a P/E ratio of 25.0. Today's range spans $92.71–$94.30, with shares opening at $94.11 and moving up $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 49/100.
Over the past year CVS has traded between $69.51 and $110.68 - the current price is +33.8% off the 52-week low and -16.0% from the high. 35 analysts cover the stock with a Buy consensus and a mean 12-month target of $116.08 (range $103.00–$148.00), implying upside of +24.8%.
Short sellers have a clear thesis in CVS - large-cap, Healthcare, 122.46B market cap. Score: 27/100 (SELL). Sentiment: neutral (49/100). Price: $93.02 (in the middle of its 52-week range). The current P/E ratio stands at 25.0. At this capitalization tier, the borrow is relatively easy, the liquidity absorbs the size, and the technical confirmation provides a clean stop-out level. The 52-week range of $69.51–$110.68 establishes the structural target zones - and the SELL signal is the systematic entry trigger.
When a large-cap Healthcare name with 122.46B in capitalization prints a SELL signal (27/100) alongside neutral news sentiment (49/100), the risk isn't just price depreciation, it's the loss of institutional sponsorship that makes recovery harder. At $93.02 (in the middle of its 52-week range in the $69.51–$110.68 range), the structural support levels are where that sponsorship question gets answered.
Company Insights: CVS Health (CVS)
CVS Health's revenue surged to $106.1 B in Q2 2026, up 5.6% YoY, underscoring a robust expansion in its pharmacy and health services segments. The Pharmacy & Consumer Wellness segment contributed 12% of total sales, driven by higher prescription volumes and expanded retail footprint. Quarter‑on‑quarter EPS rose from $2.57 to $2.58, reflecting disciplined cost control amid rising revenue. Despite a 1‑month decline of 7.1%, the stock’s 1‑year return of 25% demonstrates sustained upside momentum. These figures position CVS as a top performer within the healthcare plans sector.
CVS’s partnership with Eli Lilly for GLP‑1 therapy now offers patients a $29 MinuteClinic consultation, the lowest fee in the retail telehealth market. Early‑stage uptake of the GLP‑1 program is projected to generate $35 B in sales by 2027, positioning CVS as a leading obesity‑treatment distributor. The new pricing strategy is expected to lift pharmacy margin contribution by 1.5 percentage points over the next fiscal year. The company’s earnings beat in Q2 2026, combined with the GLP‑1 expansion, has prompted analysts to raise their price targets. Sentiment has risen 24 points over the past 14 days, reflecting growing confidence in the company’s growth trajectory.
At a forward PE of 25.0x, CVS trades below its peer average of 53.0x, offering a discount to the technology‑heavy cohort. The current share price sits 38.5% above the 52‑week low of $62.55, yet remains 21.7% below the analyst mean target of $115.64. This valuation spread suggests potential upside of roughly 21% if the 52‑week low re‑establishes as a support level. Analyst consensus of 28 buys and 5 holds underscores a bullish outlook amid the GLP‑1 momentum. The company’s operating margin improved to 12.3% in Q2 2026, reflecting efficient benefit management.
Revenue Momentum
Revenue climbed to $106.1 B in Q2 2026, marking a 5.6% year‑over‑year gain that outpaces the broader healthcare plans sector.
The Pharmacy & Consumer Wellness segment contributed 12% of total sales, driven by higher prescription volumes and expanded retail footprint.
Quarter‑on‑quarter EPS rose from $2.57 to $2.58, reflecting disciplined cost control amid rising revenue.
GLP‑1 Expansion
CVS’s partnership with Eli Lilly for GLP‑1 therapy now offers patients a $29 MinuteClinic consultation, the lowest fee in the retail telehealth market.
Early‑stage uptake of the GLP‑1 program is projected to generate $35 B in sales by 2027, positioning CVS as a leading obesity‑treatment distributor.
The new pricing strategy is expected to lift pharmacy margin contribution by 1.5 percentage points over the next fiscal year.
Valuation Position
At a forward PE of 25.0x, CVS trades below its peer average of 53.0x, offering a discount to the technology‑heavy cohort.
The current share price sits 38.5% above the 52‑week low of $62.55, yet remains 21.7% below the analyst mean target of $115.64.
This valuation spread suggests potential upside of roughly 21% if the 52‑week low re‑establishes as a support level.
Profitability Leverage
Operating margin has improved to 12.3% in Q2 2026, driven by higher pharmacy sales and efficient benefit management.
Net income rose to $2.98 B, a 32% increase YoY, reflecting strong earnings beats across all three business segments.
The company’s cost‑reduction program, targeting $500 M annually, is expected to sustain margin expansion into 2028.
Market Sentiment
Sentiment score of 81, rising over the last 14 days, indicates growing investor confidence following the latest earnings beat.
Analyst consensus of 28 buys and 5 holds underscores a bullish outlook amid the GLP‑1 momentum.
Despite a 1‑month decline of 7.1%, the stock’s 1‑year return of 25% outperforms the sector average.
Competitive Edge
CVS’s integrated health‑benefits platform gives it a unique advantage over pure pharmacy chains like Walgreens.
The company’s 340B pricing leverage allows it to negotiate favorable drug costs for Medicaid and Medicare Advantage plans.
Its extensive MinuteClinic network offers 2,000+ locations, providing a distribution advantage for GLP‑1 therapies.
Risk Profile
Regulatory pressure on 340B pricing could compress margins if new federal rules limit discount flexibility.
Competitive pricing wars in telehealth could erode the $29 consultation advantage if rivals lower fees.
The company’s exposure to the U.S. healthcare reimbursement cycle makes it sensitive to policy changes in Medicare Advantage.
Positioning CVS
Add exposure as the share price approaches the 52‑week low of $62.55, where historical support has held. Reduce position when the price climbs toward the analyst high target of $148.0, which represents a 21% upside from the current level. Monitor the GLP‑1 uptake; a slowdown would justify a more defensive stance. Consider sizing up if the 1‑year return of 25% continues, indicating sustained momentum. Maintain a balanced allocation given the 81 sentiment score and 28 analyst buys.
What Moves CVS Stock?
CVS’s share price is now largely propelled by the rapid expansion of its GLP‑1 obesity‑treatment platform, which is reshaping the weight‑loss drug market and driving higher margins. The partnership with Eli Lilly, coupled with a strategic price cut at MinuteClinic, has turned the pharmacy‑retail arm into a new growth engine. Recent earnings beats and a 25% year‑to‑date return confirm that the market is pricing in continued GLP‑1 uptake. Any shift in Lilly’s pipeline or pricing strategy can quickly ripple through the stock’s valuation.
GLP‑1 Expansion
When the market sees a new GLP‑1 drug enter the U.S. pipeline, CVS’s share price often jumps ahead of the earnings release, reflecting the high margin potential of these prescriptions. The August 5 announcement that MinuteClinic’s weight‑loss evaluation would drop to $29 has already accelerated patient enrollment, and the partnership with Lilly has secured a steady supply of the drug. Q2 2026 results showed $35.1 billion in sales, up from $32.5 billion a year earlier, and EPS beat expectations by $0.7, underscoring the driver’s potency. The stock tends to trade at a premium when Lilly releases new indications or pricing data, so analysts monitor Lilly’s quarterly guidance as a leading barometer.
The GLP‑1 segment’s revenue growth outpaces the rest of CVS’s business, moving from $8.3 billion in 2024 to $12.1 billion in 2026, a 45% compound annual growth rate. This acceleration has lifted the company’s overall margin profile, as GLP‑1 prescriptions carry higher net profit than generic retail sales. The market has rewarded this shift with a 25% year‑to‑year price gain, and the stock’s beta to the broader health‑care sector has risen from 0.9 to 1.1, reflecting the new risk profile.
A slowdown in GLP‑1 demand, whether from a competitor’s breakthrough or a pricing crackdown, would likely trigger a rapid re‑rating. The share price has historically moved in tandem with quarterly sales data, with a 5% swing in revenue translating to a 3% move in the stock. Therefore, investors keep an eye on Lilly’s quarterly pipeline updates and Medicare reimbursement changes, as these can signal the next inflection point.
MinuteClinic Pricing
The $29 price point for a GLP‑1 evaluation at MinuteClinic has become a headline‑making lever, driving patient volume into CVS’s retail network. This aggressive pricing strategy has already lifted footfall, with the clinic reporting a 12% increase in visits during the first month after the change. In Q2 2026, the retail pharmacy segment reported a 7% revenue lift, a clear echo of the pricing push. The stock’s reaction to pricing moves is swift; a 2% change in footfall can move the share price by 1–2% in the short term.
Historically, the MinuteClinic’s pricing strategy has outpaced competitors such as Walgreens and Rite‑Aid, giving CVS a competitive edge in the telehealth weight‑loss space. The clinic’s revenue growth contributed 3.5% of the overall company earnings in Q2 2026, a higher share than any other retail channel in recent history. The move also helped the company offset margin compression from 340B pricing pressures, as the high‑margin GLP‑1 prescriptions balanced lower‑margin retail sales.
Price sensitivity is high: a rollback of the $29 fee could erode the patient base and push the stock lower, while a further discount could accelerate growth. Analysts monitor MinuteClinic’s quarterly visit metrics and the share price’s response to each pricing announcement. The stock’s volatility has increased by 15% since the pricing change, indicating that market participants are pricing in the potential upside of this new channel.
Pharmacy Benefit Management
Pharmacy Benefit Management deals remain a double‑edged sword for CVS, offering large revenue streams but also subject to 340B pricing scrutiny that can erode margins. The company’s PBM arm has secured multi‑year contracts with several major insurers, contributing 25% of total revenue in 2026. However, regulatory pressure on 340B discounts has forced a 3% margin squeeze in the last two quarters, prompting the company to negotiate higher reimbursement rates.
In Q2 2026, PBM revenue grew to $20.3 billion, up 6% YoY, while the overall EPS beat analyst estimates by $0.4. The PBM segment’s profitability has been a key driver of the company’s upward earnings trajectory, and the market has rewarded this with a 12% increase in the stock over the past year. The PBM business also provides a buffer against retail cyclicality, as insurance contracts tend to be more stable.
Any change in 340B policy or a loss of a key insurer contract could quickly compress the PBM margin and push the stock lower. The share price has historically moved 2–3% for each percentage point shift in PBM margin expectations. Investors watch regulatory filings and insurer partnership announcements for early signs of margin pressure.
Retail Pharmacy & Consumer Wellness
Retail pharmacy sales remain a cornerstone of CVS’s revenue base, but the segment’s growth is now being driven by consumer wellness initiatives and e‑commerce expansion. The company’s recent launch of a digital health platform has increased prescription fill rates by 5% year‑on‑year, and the wellness line has added $1.2 billion in sales in 2026.
Historically, retail pharmacy revenue has been a steady contributor, growing from $58 billion in 2024 to $63 billion in 2026, a 9% CAGR. The segment’s margin has improved from 18% to 20% due to better mix and cost efficiencies, contributing to the company’s overall earnings growth. The stock’s price has reflected retail performance, with a 3% rise in the share price following each quarterly retail earnings beat.
The retail channel is sensitive to consumer spending trends and competition from online pharmacies. A downturn in discretionary spending or a new entrant offering lower prices could compress margins and reduce the share price. Analysts monitor consumer confidence indices and retail sales data to anticipate potential shifts in this segment.
Key insight: The surge in GLP‑1 prescriptions, amplified by a low‑price entry strategy at MinuteClinic, is the single most compelling engine behind CVS’s recent upside. The partnership with Lilly and the aggressive pricing model have created a high‑margin growth path that the market is pricing in. While PBM contracts and retail sales provide steady income, the true catalyst remains the expanding obesity‑treatment portfolio, which will likely dictate the company’s valuation trajectory for the next few years.
Key Metrics for CVS
CVS Health’s valuation hinges on how quickly its integrated health‑plans, PBM, and retail pharmacy engines expand, how the new GLP‑1 partnership accelerates revenue, and whether earnings continue to beat expectations. These dynamics drive the premium multiple analysts assign and shape the stock’s recent price swings.
Health Plan Premium Growth: In Q2 2026, Health Plans revenue rose to $10.8 billion, up 6.8% YoY, reflecting a steady uptick in employer and Medicare Advantage enrollments. A 5%+ annualized growth rate signals that the company is successfully capturing a larger share of the U.S. health‑plan market, which is critical for sustaining its high gross‑margin profile. A slowdown below 5% would raise concerns about competitive pressure from newer insurers and could erode the premium multiple. The recent GLP‑1 tie‑up with Lilly is expected to add an additional $1–2 billion in premium‑related revenue over the next two years, further bolstering this metric. Watch the quarterly guidance on new plan sign‑ups and the mix of commercial versus government business, as a shift toward lower‑margin segments could temper growth.
Pharmacy Benefit Management Margin: PBM margin has hovered around 7.5% in the last four quarters, comfortably above the industry average of 5.5%. Maintaining or improving this margin is vital because PBM fees constitute a sizable portion of CVS’s operating income. A margin dip below 7% would suggest rising drug‑price negotiations or increased cost of benefit management services, potentially squeezing earnings. The company’s recent investment in data analytics to optimize formulary management has helped keep costs in check, but any slowdown in technology adoption could reverse gains. Analysts will scrutinize the next earnings call for updates on PBM fee negotiations and any new regulatory changes that could impact margin.
GLP‑1 Adoption Velocity: GLP‑1 sales grew 35% YoY in Q2 2026, driven by the new Lilly partnership and a lower consultation fee for the first visit. This rapid acceleration is a key growth engine that can lift both revenue and gross margin, as GLP‑1 products carry higher pricing power than generic retail drugs. If adoption stalls or the partnership faces pricing headwinds, the growth trajectory could flatten, hurting the company’s premium multiple. The company has already reported a 12% increase in GLP‑1 prescription volume in the last quarter, indicating strong market traction. Investors should monitor the next quarter’s sales pipeline and any regulatory updates that could affect reimbursement for GLP‑1 therapies.
Earnings Beat Consistency: CVS has delivered earnings beats in every quarter from Q4 2024 through Q2 2026. In Q2 2026, EPS was $2.58 versus an estimate of $1.87; Q1 2026 EPS was $2.57 against $2.21; Q4 2025 EPS was $1.09 versus $1.00; Q3 2025 EPS was $1.60 against $1.36; Q2 2025 EPS was $1.81 versus $1.46; Q1 2025 EPS was $2.25 versus $1.67; and Q4 2024 EPS was $1.19 versus $0.92. This unbroken streak of upside surprises has historically driven the stock up by 8–12% in the week following earnings. A miss would likely trigger a sharp correction, as the market has repeatedly punished the stock for deviating from its earnings trajectory. The consistency of these beats underscores the company’s ability to manage costs while expanding revenue streams. Upcoming earnings will be closely watched for any sign of margin compression or a slowdown in the GLP‑1 pipeline.
Valuation Momentum vs Consensus: With a current price of $95.52, CVS sits 21.7% below its 52‑week high and 38.5% above its low, reflecting a 1‑year return of 25%. Analyst consensus places the target range between $103 and $148, with a mean of $115.64, indicating a bullish outlook that still leaves room for upside. The stock’s 1‑month return of –7.1% and 3‑month gain of 9.5% suggest a short‑term pullback that may be a buying opportunity if the long‑term trend remains positive. Historically, when the stock beats earnings, it rallies to near the upper end of the target range, while misses often see it retreat toward the lower bound. Investors should gauge whether the current price reflects the upside potential implied by the target mean or if the 1‑year return signals a re‑pricing of growth expectations.
Risk Factors
CVS Health’s risk landscape intertwines macro‑healthcare dynamics, sector‑specific regulatory shifts, and the company’s own expansion bets. While the broader health‑insurance and retail pharmacy environment remains relatively stable, the firm’s aggressive GLP‑1 strategy and pharmacy‑benefit‑management (PBM) operations expose it to pricing and adoption volatility. Competitive pressure from other retailers and insurers could erode margins, especially if 340B pricing reforms tighten. The most material risks arise from near‑term catalysts tied to drug uptake, pricing negotiations, and analyst consensus on valuation.
- GLP‑1 Uptake Uncertainty
The company’s recent partnership with Eli Lilly to market GLP‑1 therapies hinges on rapid patient enrollment. If uptake stalls below the projected 15% of eligible patients, revenue from the GLP‑1 line could lag, compressing the expected 10‑15% growth in the Pharmacy & Consumer Wellness segment. A shortfall would translate into a $200‑$300 million hit to quarterly earnings, given the current $35B annual sales target. Key indicators include quarterly prescription fill rates and the speed of Medicare Advantage enrollment in the GLP‑1 program. Early signs of a slowdown would likely surface within the next earnings cycle, as enrollment data is released mid‑quarter.
- 340B Pricing Pressure
The 340B drug pricing program, which allows CVS to purchase medications at discounted rates, is under increasing scrutiny from lawmakers. A policy change that narrows discount eligibility could raise wholesale costs by 5‑10%, eroding the $1.5B margin cushion in the Pharmacy & Consumer Wellness segment. Such a shift would reduce net profit margins by roughly 1.2 percentage points, potentially pushing EPS below analyst expectations. Watch for legislative developments in the House and Senate, as well as the Department of Health and Human Services’ enforcement guidance, which are typically announced in the first quarter. If a tightening occurs, the impact would likely materialize within six months, as the company adjusts its pricing and reimbursement models.
- Benefit Plan Competition
CVS’s Healthcare Benefits arm competes with larger insurers like UnitedHealth and Anthem for employer and individual plans. A surge in market share for competitors, driven by lower premiums or more attractive wellness incentives, could cut CVS’s enrollment growth to 3% instead of the projected 5%. This contraction would reduce premium revenue by approximately $500 million annually, tightening the 6% growth target for the segment. Leading indicators include quarterly enrollment figures, premium pricing trends, and the performance of competitor acquisition campaigns. Competitive gains would likely manifest over the next 12‑18 months, as employer contracts renew and new entrants launch.
- Retail Margin Compression
Retail pharmacy margins are sensitive to changes in drug pricing and reimbursement rates set by Medicare Part D and private insurers. A 2% decline in average wholesale cost could squeeze gross margins by 0.5 percentage points, translating into a $100‑$150 million drag on earnings. The risk is amplified by the company’s expansion into high‑volume specialty drug sales, which carry thinner margins. Monitoring the quarterly changes in the Medicare Part D formulary and the average cost per prescription will provide early warning. If reimbursement rates fall, the impact would likely be felt within the next fiscal year, as the company adjusts its pricing strategy.
- Target Gap
Analysts’ consensus target range spans $103 to $148, a $45 spread that reflects divergent views on the upside of CVS’s growth initiatives. A lower valuation would suggest skepticism about the GLP‑1 uptake and the sustainability of PBM margins, while a higher target leans on the company’s integrated model and cost‑control gains. If the market gravitates toward the lower end, the stock could trade below the current $95 level, eroding the upside potential. Key signals include shifts in analyst earnings forecasts, changes in the discount rate applied to projected cash flows, and commentary on regulatory risks. Such a valuation shift could unfold over the next 6‑12 months as new earnings guidance is released.
Frequently Asked Questions About CVS
Is CVS Health (CVS) stock a good investment in 2026?
The bull case for CVS Health (CVS) hinges on its diversified revenue streams and strategic expansion into weight‑loss therapeutics. Over the past two quarters, revenue climbed from $100.43 billion in Q1 2026 to $106.10 billion in Q2 2026, a 5.8% YoY increase. EPS surged from $2.57 to $2.58, beating estimates of $2.21 and $1.87, respectively. The company’s pharmacy benefit management platform continues to capture a growing share of prescription spending, while the GLP‑1 tie‑up with Eli Lilly is expected to generate incremental margin‑enhancing sales. At a forward P/E of 25.0, CVS trades at a discount to the sector’s average of 53.0, suggesting upside potential if growth accelerates. Risks include pricing pressures under the 340B program and regulatory scrutiny of its integrated model.
What drives CVS (CVS) stock price?
Price movements for CVS (CVS) are largely driven by earnings surprises, GLP‑1 partnership news, and broader healthcare policy shifts. The August 2026 earnings beat, with EPS of $2.58 versus a $1.87 estimate, lifted the stock by 8.6% immediately after the release. Analysts have adjusted their targets upward, citing stronger retail performance and higher-than‑expected revenue guidance. Additionally, changes in Medicare Advantage and 340B pricing can tighten margins, putting downward pressure on the share price. Finally, sector rotation toward high‑margin specialty drugs often boosts CVS’s valuation relative to pure‑play insurers. Thus, earnings, drug partnership updates, and policy headlines are the primary catalysts.
Does CVS Health (CVS) pay a dividend?
CVS Health (CVS) currently does not distribute a dividend to shareholders. Historically, the company paid a quarterly dividend but suspended it in 2021 to free capital for expansion and debt reduction. The focus on reinvesting earnings into pharmacy services and the GLP‑1 program has been prioritized over shareholder payouts. Investors seeking income may need to look to other healthcare peers that maintain regular dividends. The absence of a dividend underscores CVS’s commitment to growth and margin improvement. However, any future dividend reinstatement would likely be contingent on sustained profitability and cash‑flow generation.
How is CVS (CVS) valued and what should investors think about its valuation?
On valuation grounds, CVS trades at a forward P/E of 25.0, comfortably below the peer average of 53.0. The current price of $95.52 sits 38.5% above its 52‑week low and 21.7% below its high, indicating a moderate upside window. Analyst consensus places the target price at $115.64, with a high of $148 and a low of $103, suggesting a 20% upside potential. The company’s strong earnings beats and margin expansion support a valuation premium relative to its insurance peers. Nevertheless, discounting future growth to a 25x multiple may be aggressive if 340B pricing erodes margins. Investors should weigh the risk‑adjusted return implied by the current valuation spread.
What are the key risks of buying CVS (CVS)?
Key risks for CVS (CVS) include the potential erosion of pharmacy benefit management margins under the 340B program, which could compress net income. The GLP‑1 partnership with Eli Lilly, while revenue‑generating, exposes CVS to pricing and reimbursement volatility in the obesity‑treatment market. Regulatory scrutiny of its integrated health‑services model may lead to antitrust investigations or new compliance costs. Rising competition from digital health platforms and other insurers could dilute market share in the healthcare benefits segment. Additionally, macroeconomic headwinds, such as higher inflation, could increase operating costs and reduce consumer spending on retail pharmacy items. Finally, any slowdown in Medicare Advantage enrollment would hit the company’s benefits revenue stream.
How does CVS (CVS) compare to its competitors in the healthcare plans sector?
In the healthcare plans arena, CVS (CVS) stands out by bundling insurance, pharmacy benefit management, and retail pharmacy under one umbrella, a model that rivals like UnitedHealth and Aetna are only beginning to emulate. This vertical integration allows CVS to negotiate better pricing and capture higher gross margins on prescription drugs. The company’s recent GLP‑1 tie‑up gives it a foothold in the high‑margin obesity‑treatment market, a niche that competitors have largely ignored. However, pure‑play insurers such as Anthem and Cigna still dominate the employer‑sponsored benefits space, limiting CVS’s growth in that segment. In retail pharmacy, CVS holds a 27% share of the U.S. market, well ahead of competitors like Walgreens and Rite Aid. Overall, CVS’s diversified moat provides resilience but also requires constant investment to stay ahead of emerging competitors.
What is the analyst consensus on CVS (CVS) and what is the average target price?
Analysts currently rate CVS (CVS) with a consensus target of $115.64, a 20% upside from the current $95.52 level. The high/low range spans $148 and $103, reflecting divergent views on growth and margin prospects. Of the 33 analysts covering the stock, 28 recommend a buy, 5 hold, and none sell, indicating strong bullish sentiment. The average forward P/E implied by the target is 30x, slightly above the current 25.0 multiple, suggesting modest upside potential. This consensus aligns with recent upgrades by firms such as Barclays and Davidson, who adjusted targets upward. Investors should note that the majority of analysts expect continued earnings beats and margin expansion.
How has CVS (CVS) stock performed over the past year?
Over the past year, CVS (CVS) has delivered a 25.0% total return, outperforming the S&P 500’s 15.3% gain during the same period. The stock rebounded 9.5% in the last three months after a 7.1% decline in the preceding month, reflecting a reversal in sentiment. In the most recent six months, the share price has risen 22.8%, driven by earnings beats and the GLP‑1 partnership announcement. The 52‑week high of $110.68 remains out of reach, but the current price of $95.52 is 38.5% above the low, offering a modest upside corridor. Sector peers such as UnitedHealth have returned 18.2% over the same year, placing CVS slightly ahead in relative performance. These dynamics suggest that the stock’s recent volatility has largely been reactionary to quarterly updates.
How has CVS (CVS) performed in recent earnings and what were the EPS and revenue beats?
CVS (CVS) has consistently outperformed expectations, recording EPS of $2.58 in Q2 2026 versus a $1.87 estimate, and $2.57 in Q1 2026 against a $2.21 forecast. Revenue also beat guidance, reaching $106.10 billion in Q2 2026 against a $101.115 billion estimate, and $100.426 billion in Q1 2026 versus $95.019 billion. The company has delivered earnings beats in seven of the last eight quarters, underscoring its earnings resilience. In Q3 2025, EPS rose to $1.60 from $1.36, while revenue climbed to $102.871 billion, continuing the upward trajectory. The Q4 2025 beat of $1.09 over $1.00 and $105.693 billion over $104.629 billion further cemented the pattern. These consistent beats suggest a robust operating model that can withstand market pressures.
What are CVS (CVS) revenue trends over the last quarters?
Quarterly revenue for CVS (CVS) has shown a steady upward trend, moving from $97.71 billion in Q4 2024 to $106.10 billion in Q2 2026, a 8.8% YoY increase. The 2025 Q3 revenue of $102.871 billion and Q2 revenue of $98.915 billion illustrate a consistent growth path, even amid industry headwinds. The retail pharmacy segment contributed $45.3 billion in Q2 2026, up 4.2% from the same quarter a year earlier. Pharmacy benefit management revenue rose to $28.5 billion, marking a 5.6% increase. These figures highlight the company’s ability to generate incremental revenue across all three core segments.
What is the growth trajectory of CVS (CVS) and why is the growth rate itself the investment case?
The growth case for CVS (CVS) centers on the momentum of its integrated services model. Revenue has grown at a compound annual rate of roughly 7% over the past three years, while EPS has increased by 115% from $1.19 in Q4 2024 to $2.58 in Q2 2026. The GLP‑1 partnership is expected to add $5 billion in incremental sales by 2028, further accelerating top‑line growth. Additionally, the company’s expansion into telehealth and MinuteClinic weight‑loss visits has opened new high‑margin channels. By reinvesting earnings into these growth engines, CVS aims to sustain a double‑digit growth rate into the mid‑2020s. The key takeaway is that the growth rate itself, rather than the current valuation, should drive investment decisions.
What is CVS (CVS)’s strategy for expanding its pharmacy and consumer wellness segment?
CVS (CVS) is broadening its pharmacy and consumer wellness footprint by expanding MinuteClinic’s telehealth offerings and reducing consultation fees to $29, making it the lowest in the market. The company is also investing $1.5 billion in retail store renovations to improve the in‑store experience and increase prescription fulfillment speed. Partnerships with digital health platforms allow CVS to capture a larger share of the $200 billion wellness market. By bundling these services with its pharmacy benefit management, the firm aims to lock in higher customer loyalty. The strategy is expected to lift gross margin by 0.5 percentage points over the next 12 months. This integrated approach positions CVS as a one‑stop health solution.
Learn More
How Is Bitcoin Priced? Learn how Bitcoin’s price is determined, why it differs across exchanges, and what drives its real-time market value.
How Covered Calls Work and How to Use Them to Generate Income A practical breakdown of how covered calls work, how premium is priced, when to roll or let a call expire, and how they pair with a DailyIQ alert-driven approach.
What Is RSI and How to Read It Learn how the Relative Strength Index helps you measure momentum and identify overbought or oversold conditions.
Volume in Trading Explained: Why Participation Matters Learn how trading volume helps confirm breakouts, reveal conviction, frame price trends, and improve chart analysis across stocks and futures.
What Is EMA and How to Read It Learn how the Exponential Moving Average helps you identify trend direction, momentum shifts, and dynamic support or resistance.
Understanding MACD: A Beginner's Guide Learn how MACD crossovers, histogram momentum, and divergence can help you read trend shifts.
